- Home
- VOR
as 12-20-2024 4:00pm EST
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 57.1M | IPO Year: | 2021 |
| Target Price: | $11.36 | AVG Volume (30 days): | 577.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.63 - $3.14 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Vor Biopharma Inc. News
VOR Breaking Stock News: Dive into VOR Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 days ago
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
GlobeNewswire
a month ago
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
GlobeNewswire
a month ago
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
MT Newswires
3 months ago
Vor Biopharma Names Han Choi as Chief Financial Officer
GlobeNewswire
3 months ago
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
MT Newswires
4 months ago
Sector Update: Health Care
MT Newswires
4 months ago
Vor Biopharma Reports Positive Trem-Cell Study Data; Shares Rise
GlobeNewswire
4 months ago
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
Compare VOR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VOR Vor Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.